title: Localised and unresectable neuroblastoma in infants: excellent outcome with primary chemotherapy. Neuroblastoma Study Group, Société Française d'Oncologie Pédiatrique.
abstract: METHODS
  Infants with neuroblastoma (NB) were assessed according to INSS recommendations, including MIBG scan and extensive bone marrow staging to eliminate metastatic spread. Patients with unresectable tumour received chemotherapy, including two courses of carboplatin-etoposide (CE) and two of vincristinecyclophosphamide-doxorubicin (CAdO). Post-operative treatment was to be given only in infants with MYCN amplification. Between 1990 and 1994, 52 consecutive children were registered.
  
  
  RESULTS
  Among the 44 patients who received CE as a first course, the response rate was (66%) and the primary could be removed in all children but one, who was in remission. The toxicity was mainly haematological and was always manageable. The 5 year overall survival (OS) and event-free survival (EFS) were 94 and 90 +/- 8%, respectively, with a median follow-up of 48 months. The outcome of infants with no MYCN amplification was excellent; OS and EFS were, respectively, 97 and 94%.
  
  
  CONCLUSIONS
  Chemotherapy allows surgical excision and excellent outcome in infants with localised and unresectable NB. Less intensive Chemotherapy should be investigated in such patients.
authors.affiliation: Unité d'Hemato-Oncologie Pediatrique, Hĵpital des Enfants, Toulouse, France. rubie.h@chu-toulouse.fr
authors.forename: H
authors.initials: H
authors.lastname: Rubie
authors.forename: D
authors.initials: D
authors.lastname: Plantaz
authors.forename: C
authors.initials: C
authors.lastname: Coze
authors.forename: J
authors.initials: J
authors.lastname: Michon
authors.forename: D
authors.initials: D
authors.lastname: Frappaz
authors.forename: M C
authors.initials: MC
authors.lastname: Baranzelli
authors.forename: P
authors.initials: P
authors.lastname: Chastagner
authors.forename: M C
authors.initials: MC
authors.lastname: Peyroulet
authors.forename: O
authors.initials: O
authors.lastname: Hartmann
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005784:Gene Amplification; D016259:Genes, myc; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D015993:Life Tables; D008297:Male; D009367:Neoplasm Staging; D009447:Neuroblastoma / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D011183:Postoperative Complications / Q000401:mortality; D018714:Radiotherapy, Adjuvant; D012074:Remission Induction; D016019:Survival Analysis; D015996:Survival Rate; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D016190:Carboplatin